Related Experiment Videos
Comparison of thrombin and ristocetin in the interaction between von Willebrand factor and platelets
Abstract:
It is known that the antibiotic ristocetin exposes the platelet membrane receptor for factor VIII/von Willebrand glycoprotein (FVIII/vWF). Recent reports suggest that low concentrations of thrombin also cause platelet membrane receptors to become available for FVIII/vWF. As a consequence, the suspicion has been raised that thrombin provides similar or equivalent activity in vivo to that observed for ristocetin under in vitro conditions. In this study, we quantitated the extent to which thrombin promotes the binding of FVII/vWF to platelets and determined whether or not this interaction initiates or complements platelet aggregation. With ristocetin present, the amount of 125I-FVIII/vWF that became platelet-bound correlated closely with the onset, rate, and extent of platelet aggregation. In contrast, at every thrombin concentration tested, the amount of 125I-FVIII/vWF that specifically bound to platelets was about 6% of that observed with ristocetin. Significantly, FVIII/vWF did not augment the rate of aggregation of platelets in response to thrombin or initiate platelet aggregation when subaggregating doses of thrombin were used. These observations indicate that the minimal association that occurs between FVIII/vWF and the platelet membrane in the presence of thrombin does not correlate with platelet aggregation and therefore is not analogous to the effects of ristocetin. Whether the low level of binding relates to another process, such as platelet-endothelial interactions, remains unknown.
Insights
Thrombin minimally binds factor VIII/von Willebrand glycoprotein (FVIII/vWF) to platelets, unlike ristocetin. This low binding does not trigger or enhance platelet aggregation, suggesting a different mechanism than ristocetin.
Area of Science:
- Hematology
- Biochemistry
- Molecular Biology
Background:
- Ristocetin is known to expose platelet receptors for factor VIII/von Willebrand glycoprotein (FVIII/vWF).
- Recent studies suggest low thrombin concentrations may also make these receptors available.
- This raises questions about thrombin's in vivo role compared to ristocetin's in vitro effects.
Purpose of the Study:
- To quantify thrombin-induced FVIII/vWF binding to platelets.
- To determine if this interaction initiates or complements platelet aggregation.
- To compare thrombin's effect with ristocetin's known mechanism.
Main Methods:
- Quantification of 125I-FVIII/vWF binding to platelets.
- Assessment of platelet aggregation in response to thrombin and ristocetin.
- Comparison of FVIII/vWF binding levels under different conditions.
Main Results:
- Ristocetin-induced FVIII/vWF binding strongly correlated with platelet aggregation onset, rate, and extent.
- Thrombin-induced FVIII/vWF binding was significantly lower, approximately 6% of that with ristocetin.
- FVIII/vWF did not enhance thrombin-induced aggregation or initiate aggregation with sub-threshold thrombin doses.
Conclusions:
- Minimal FVIII/vWF association with platelets induced by thrombin does not correlate with platelet aggregation.
- Thrombin's effect on FVIII/vWF-platelet interaction is not analogous to ristocetin's.
- The biological significance of low-level FVIII/vWF binding in the presence of thrombin remains to be elucidated, possibly involving other interactions.